U.S. Military Testosterone Screening: Why Context Matters More Than a Single Result

Last updated: July 19, 2026

On July 15, 2026, U.S. Secretary of Defense Pete Hegseth announced plans to introduce annual screening for testosterone deficiency among active-duty and reserve service members aged 30 and older. Younger personnel would be able to request testing voluntarily.

The announcement, presented under the “High-T Department” label, garnered significant public and medical attention. It also raised a practical clinical question: how much can a single testosterone result actually tell us about a man’s health, recovery, and physical readiness?

Usually, not enough.

Testosterone plays an important role in sexual function, muscle and bone health, red blood cell production, fertility, and several metabolic processes. However, circulating levels are influenced by sleep, food intake, body composition, illness, medication use, physical training, psychological stress, and the time at which blood is collected.
A low result from a single blood test does not establish a diagnosis of hypogonadism. It is also not, by itself, an indication for testosterone replacement therapy.
The potential value of the Pentagon’s initiative will therefore depend less on how many tests are performed and more on how carefully the results are interpreted.

Why Testosterone May Decline in Military Personnel
Military personnel—particularly those serving in special operations units—may be exposed to several factors that affect the hypothalamic–pituitary–gonadal axis, the hormonal system that regulates testosterone production.
These factors include:

• chronic sleep restriction;
• intense or prolonged physical exertion;
• inadequate calorie and nutrient intake;
• repeated training and deployment cycles;
• psychological stress;
• chronic pain;
• traumatic brain injury;
• blast exposure;
• disruption of circadian rhythms;
• the use of opioids and certain other medications;
• insufficient recovery between periods of high demand.

During extreme physical or environmental stress, the body may temporarily reduce reproductive and anabolic activity while prioritizing more immediate physiological demands.

Military training studies have documented changes not only in testosterone, but also in cortisol, thyroid hormones, insulin-like growth factor 1, or IGF-1, and other metabolic markers. In some studies, testosterone levels began to recover within days after the most demanding phase of training ended.

This distinction matters. A temporarily low result after severe sleep deprivation, calorie restriction, or intensive field training is not necessarily evidence of chronic endocrine disease.

What the Study of Elite Military Operators Actually Found

A figure frequently cited in discussions of military testosterone screening is 43%.
It comes from a study of 65 active-duty U.S. naval special operators. Twenty-eight participants had total testosterone concentrations below the age-adjusted reference threshold used by the investigators.
Some participants also had changes in sex hormone–binding globulin, or SHBG, cortisol, and thyroid-related biomarkers.
The finding is clinically interesting, but it must be interpreted cautiously.
This was a small, cross-sectional study. It measured participants at a single point in time and therefore provides limited evidence about prevalence, persistence, or causality.

The study could not determine:

• whether the low values were temporary;
• whether they were present before military service;
• whether they were caused by occupational exposures;
• whether they were associated with symptoms;
• whether the results would have remained low on repeat testing;
• whether participants met accepted diagnostic criteria for hypogonadism.

The sample was also highly specialized and cannot be considered representative of the entire U.S. military, all special operations personnel, or the general male population.
The study supports further research into the endocrine health of high-demand military populations. It does not show that 43% of service members have clinically confirmed testosterone deficiency.

What Is “Operator Syndrome”?
“Operator Syndrome” is a proposed clinical construct used to describe a recurring cluster of health problems reported in some active-duty and former special operations personnel.
The proposed cluster may include:

• repeated mild traumatic brain injury;
• blast-wave exposure;
• chronic pain;
• sleep disturbance;
• post-traumatic stress symptoms;
• depression;
• cognitive difficulties;
• hormonal or metabolic abnormalities;
• reduced libido;
• emotional detachment;
• impaired family or social functioning.

Operator Syndrome is not a formally recognized diagnosis with universally accepted diagnostic criteria. It is not established as a distinct disorder in major international disease classification systems.
Rather, it is a framework intended to describe a complex pattern of neurological, psychological, endocrine, sleep-related, and pain-related problems that may overlap in some military operators.
Its biological mechanisms, diagnostic boundaries, and clinical usefulness remain under investigation.
Low testosterone may be one component of this pattern, but it should not be treated as the sole cause of fatigue, reduced performance, mood symptoms, or cognitive difficulties.
Why Large-Scale Screening Requires Caution
The proposed Department of Defense program could generate valuable longitudinal data and increase awareness of men’s hormonal health.

However, routine testing of large populations also creates a risk of overdiagnosis.
Current endocrine guidelines generally do not recommend population-wide testosterone screening in men who have no relevant symptoms or clinical risk factors.
A diagnosis of male hypogonadism usually requires:

1. Symptoms or objective signs consistent with androgen deficiency.
2. Unequivocally low testosterone levels.
3. Confirmation with a second properly collected morning sample.
4. Evaluation of the underlying cause.

The problem is therefore not the blood test itself. The problem is treating an isolated laboratory value as a diagnosis.
A single low result may reflect:

• a poor night’s sleep;
• acute illness;
• recent strenuous exercise;
• severe calorie restriction;
• obesity;
• alcohol use;
• medication effects;
• laboratory variation;
• an inappropriate time of sample collection.

Without clinical context and repeat testing, the result may be misleading.
Low Testosterone Is Not the Same as Hypogonadism
Testosterone concentrations fluctuate. A man can have a temporarily low result without structural disease of the testes, pituitary gland, or hypothalamus.
Clinical hypogonadism is diagnosed when compatible symptoms are accompanied by consistently low hormone levels.
The most specific symptoms are sexual:

• reduced libido;
• fewer spontaneous or morning erections;
• erectile dysfunction;
• reduced sexual activity.

Other possible features include:

• reduced muscle mass;
• lower bone mineral density;
• infertility;
• unexplained anemia;
• hot flushes in severe cases;
• decreased body hair;
• reduced testicular volume.

Fatigue, low mood, poor concentration, irritability, reduced motivation, and weight gain may also occur. However, these symptoms are nonspecific.
They can also be caused by:

• depression;
• chronic stress;
• sleep apnea;
• thyroid disease;
• anemia;
• diabetes;
• obesity;
• chronic liver disease;
• medication use;
• overtraining;
• insufficient calorie intake.

For this reason, laboratory results must be interpreted alongside symptoms, medical history, medication use, physical findings, and other biomarkers.

Should Every Man Over 30 Be Tested Annually?

Not necessarily.

Age alone is not considered sufficient reason for routine annual testing in an otherwise healthy, asymptomatic man.

Testing is more appropriate when symptoms or recognized risk factors are present.

These may include:

• reduced sexual desire;
• fewer morning erections;
• unexplained erectile dysfunction;
• infertility;
• loss of muscle mass;
• reduced bone density;
• unexplained anemia;
• pituitary disease;
• testicular disease or injury;
• long-term opioid treatment;
• treatment with certain glucocorticoids;
• substantial obesity;
• type 2 diabetes accompanied by relevant symptoms;
• previous chemotherapy or radiotherapy;
• repeated or severe traumatic brain injury;
• prolonged exposure to extreme physical stress or energy deficiency.

For military personnel, first responders, professional athletes, shift workers, and people in other high-demand occupations, hormonal testing may be useful as part of a broader health and recovery assessment.
It should not be used as a stand-alone measure of operational readiness, resilience, masculinity, or performance.

How Testosterone Testing Should Be Performed

Test in the Morning
Total testosterone is generally measured between 7:00 and 10:00 a.m., when levels are usually highest.
The timing may need to be adjusted for shift workers or men with an unusual sleep schedule. In such cases, the sample should ideally be collected after the person’s main sleep period.

Test in a Fasting State
Food intake can temporarily affect testosterone concentrations. Morning testing while fasting provides more standardized conditions.

Repeat an Abnormal Result
A low result should usually be confirmed with a second morning sample collected on a different day.
Diagnosis should not be based on a single measurement.

Avoid Testing During Acute Physiological Stress
Results may be temporarily altered by:

• acute illness;
• severe sleep loss;
• strenuous exercise;
• military field training;
• significant calorie restriction;
• heavy alcohol consumption;
• recent injury.

Where clinically appropriate, testing should be repeated after the acute stressor has resolved.

Use a Reliable Laboratory
Different assay methods may produce different results from the same sample.
Whenever possible, repeat testing should be performed using the same laboratory and a standardized, quality-controlled method.

What Level Is Considered Low?
There is no single numerical threshold that establishes hypogonadism in every man.
In U.S. practice, a total testosterone concentration of approximately 300 ng/dL, or about 10.4 nmol/L, is commonly used as a diagnostic reference point.
Some European guidelines use a threshold closer to 12 nmol/L, provided the result is repeatedly low and accompanied by compatible symptoms.
The difference between thresholds reflects variation in:

• laboratory methods;
• reference populations;
• clinical objectives;
• SHBG concentrations;
• patient age;
• guideline methodology.

A value just below a laboratory reference range does not automatically confirm disease. Likewise, a total testosterone result within the reference range does not always exclude low free testosterone.

Why Total Testosterone Alone May Be Misleading
Most circulating testosterone is bound to proteins.
It exists in three main forms:

• tightly bound to SHBG;
• loosely bound to albumin;
• unbound, or free.

Only a small proportion circulates as free testosterone.
Changes in SHBG can substantially alter total testosterone without producing an equivalent change in the biologically available fraction.

For example:

• obesity and insulin resistance are often associated with low SHBG, which can make total testosterone appear lower;
• hyperthyroidism, some liver disorders, certain medications, and aging may increase SHBG;
• when SHBG is high, total testosterone may appear normal even though free testosterone is reduced.

In men with borderline total testosterone, abnormal SHBG, or symptoms that do not match the total result, free testosterone should be calculated or measured using an appropriate method.

Biomarkers That Help Explain a Low Testosterone Result

A broader laboratory panel can help determine whether a low result reflects testicular dysfunction, central hormonal suppression, metabolic disease, medication effects, or a temporary physiological response.

Interpreting LH and FSH

Low testosterone with elevated LH and FSH is more consistent with primary hypogonadism, in which the testes are not responding adequately to pituitary stimulation.
Low testosterone with low or inappropriately normal LH may suggest secondary hypogonadism or functional suppression at the hypothalamic or pituitary level.

Possible causes include:

• obesity;
• severe energy deficiency;
• hyperprolactinemia;
• opioid use;
• pituitary disease;
• systemic illness;
• extreme physical stress.

The pattern is often more informative than any single result.

Additional Biomarkers: Useful in Context, but Not for Everyone
Cortisol and the Testosterone-to-Cortisol Ratio
The testosterone-to-cortisol ratio has been studied in military and sports physiology as a possible marker of the balance between anabolic activity and physiological stress.
It may change during periods of intense training, calorie restriction, or inadequate recovery.

However:

• individual variation is substantial;
• there are no universally accepted diagnostic cutoffs;
• it is not part of the standard diagnostic pathway for male hypogonadism;
• it cannot independently diagnose overtraining or “operator fatigue”;
• it should not be used as an indication for testosterone treatment.

The ratio may provide contextual information in research or longitudinal performance monitoring, but it is not a stand-alone clinical test.

IGF-1
IGF-1 may decrease during severe energy deficiency, systemic illness, or extreme training stress.
Routine measurement is not necessary in every man with low testosterone. It is more relevant when growth hormone dysfunction or pituitary disease is suspected.

hs-CRP and IL-6
Inflammatory markers may help identify systemic inflammation, infection, obesity-related inflammation, or physiological stress.
They are nonspecific and cannot diagnose androgen deficiency.

Vitamin D, Zinc, and Magnesium
Deficiencies should be corrected when they are confirmed or clinically likely.
However, supplementation has not been shown to reliably raise testosterone in men whose levels of these nutrients are already adequate.

Common Laboratory Patterns and What They May Suggest
Low Total Testosterone, Low SHBG, and Obesity
This pattern is common in insulin resistance and obesity-related functional hypogonadism.
Because SHBG is low, the reduction in free testosterone may be less pronounced than the total value suggests.

Low Testosterone with Elevated LH and FSH
This pattern may indicate impaired testicular function.
Potential causes include:

• previous testicular injury;
• infection;
• surgery;
• chemotherapy;
• genetic conditions;
• toxic exposure;
• age-related testicular dysfunction.

Low Testosterone with Low or Normal LH
This may reflect:

• functional suppression;
• severe obesity;
• inadequate energy intake;
• opioid use;
• hyperprolactinemia;
• pituitary or hypothalamic disease.

Normal Total Testosterone with High SHBG
Free testosterone may still be low.
Possible explanations include:

• hyperthyroidism;
• liver disease;
• certain medications;
• aging.

Low Testosterone, Elevated HbA1c, and Abnormal Liver Enzymes
This pattern may point toward a broader metabolic problem rather than an isolated reproductive disorder.
Relevant considerations include:

• insulin resistance;
• type 2 diabetes;
• visceral obesity;
• metabolic dysfunction-associated steatotic liver disease.

These examples show why interpreting biomarkers as a connected system is more informative than reviewing each value independently.

How Aima Diagnostics Supports Hormonal Test Interpretation
A conventional laboratory report usually compares each result with a population reference interval.
That approach is useful, but limited. It does not always explain how several abnormalities may be related or whether a result has changed meaningfully over time.

Aima Diagnostics supports structured online interpretation of laboratory results by considering:

• age and sex;
• symptoms and clinical context;
• sample collection time;
• current medications;
• body weight and lifestyle factors;
• comorbid conditions;
• total and free testosterone;
• SHBG, LH, FSH, and prolactin;
• thyroid function;
• glucose metabolism;
• liver-related biomarkers;
• previous laboratory findings;
• changes across multiple test dates.

The aim is not simply to label a result as high or low. It is to identify clinically relevant patterns and help explain what may warrant confirmation or further investigation.
For example, an integrated analysis may highlight that:

• low total testosterone is accompanied by low SHBG and metabolic abnormalities;
• hormone levels changed after a period of sleep deprivation or intense training;
• LH and FSH do not show the expected physiological response;
• prolactin should be repeated under standardized conditions;
• a result differs substantially from the patient’s previous baseline;
• additional testing may be appropriate before treatment is considered.

Aima Diagnostics does not replace an endocrinologist, urologist, primary care physician, or other qualified healthcare professional.
Its role is to organize laboratory information, identify meaningful relationships, and support a more informed discussion between the patient and clinician.

Why Longitudinal Trends Matter
A single laboratory result is a snapshot.
Repeated measurements, collected under comparable conditions, can show whether a change is persistent, progressive, or temporary.
For more reliable longitudinal monitoring, it is helpful to use:

• the same laboratory;
• the same or a comparable time of day;
• fasting morning samples;
• a consistent sleep schedule;
• similar training conditions;
• testing outside periods of acute illness;
• documentation of body weight, symptoms, medications, and major lifestyle changes.

This is particularly relevant in military medicine, occupational health, and elite sport.
A temporary decline during intensive training may require recovery and repeat testing. A persistent decline accompanied by symptoms and abnormal gonadotropins may require a more extensive endocrine evaluation.

Evidence-Based Ways to Support Healthy Testosterone Levels
There is no safe intervention that guarantees a substantial increase in testosterone for every man.
However, functional reductions may improve when reversible causes are addressed.

Reduce Excess Body Weight
Obesity is one of the most common reversible contributors to low testosterone.
Weight loss in men with obesity is often associated with increases in total testosterone, SHBG, and, in some cases, free testosterone.

The effect is generally greater when weight loss is clinically meaningful and sustained.
Lifestyle intervention is therefore considered a first-line strategy in men with obesity-related functional hypogonadism.

Avoid Chronic Energy Deficiency
Severe or prolonged calorie restriction can suppress the reproductive axis.
This is particularly relevant to:

• military personnel during field exercises;
• endurance athletes;
• athletes undergoing aggressive weight cutting;
• men combining intense training with restrictive diets;
• people performing prolonged physically demanding work.

Adequate energy availability, sufficient protein, and balanced nutrition are more important than any single “testosterone-boosting” food.

Prioritize Sleep and Circadian Stability
Testosterone secretion is closely linked to sleep.
Severe sleep deprivation can lower circulating levels, while disrupted sleep may also worsen insulin resistance, appetite regulation, mood, and recovery.
Improving sleep does not guarantee a dramatic rise in testosterone, but it removes an important confounding factor and supports overall endocrine health.
Men with loud snoring, witnessed breathing pauses, morning headaches, or marked daytime sleepiness should be assessed for obstructive sleep apnea.

Combine Resistance and Aerobic Exercise
Regular physical activity can improve:

• body composition;
• insulin sensitivity;
• cardiovascular health;
• muscle mass;
• sleep quality.

Resistance training is particularly useful for preserving muscle and strength.
However, excessive training without adequate sleep, nutrition, and recovery may suppress rather than improve the hormonal profile.

Reduce Heavy Alcohol Use
Chronic heavy alcohol consumption can impair testicular function, liver metabolism, fertility, and regulation of the reproductive axis.
Reducing alcohol intake may improve both hormonal and broader metabolic health.

Review Medications with a Clinician
Long-term opioid use is a well-established cause of central hypogonadism.
Other medications may also affect testosterone, SHBG, prolactin, or sexual function.
Prescribed treatment should not be stopped without medical advice. The potential endocrine effects should instead be reviewed with the treating clinician.

Avoid Anabolic Steroids and Unregulated “Boosters”
Exogenous anabolic-androgenic steroids suppress LH and FSH, reducing the body’s own testosterone production and sperm formation.
Recovery after discontinuation may take months or longer. In some men, fertility and endocrine function do not fully recover without medical treatment.
Over-the-counter products marketed as testosterone boosters may contain ineffective ingredients, inaccurate doses, or undeclared pharmacologically active compounds.
Correct Documented Deficiencies
Vitamin D, zinc, magnesium, iron, and other nutrients should be corrected when deficiency is confirmed.
Taking high doses in the absence of deficiency is unlikely to provide a meaningful hormonal benefit and may cause harm.

Treat the Underlying Condition
Low testosterone may improve when the primary problem is addressed.
Relevant conditions include:

• obesity;
• type 2 diabetes;
• thyroid disease;
• hyperprolactinemia;
• chronic liver disease;
• sleep apnea;
• depression;
• chronic pain;
• pituitary disease.

In functional hypogonadism, treating the underlying cause may restore the hormonal profile without lifelong testosterone therapy.

When Testosterone Replacement Therapy May Be Appropriate
Testosterone replacement therapy may benefit men with confirmed hypogonadism, particularly when the cause is an organic disorder of the testes, pituitary gland, or hypothalamus.
It should not be prescribed solely for fatigue, reduced motivation, or one borderline laboratory result.
Before treatment, the clinician should usually assess:

• symptoms and physical findings;
• at least two morning testosterone measurements;
• LH and FSH;
• SHBG and free testosterone when indicated;
• prolactin;
• hematocrit;
• cardiovascular risk;
• prostate-related risk where appropriate;
• fertility plans.

Testosterone Therapy and Fertility
Exogenous testosterone suppresses pituitary gonadotropins and can substantially reduce sperm production.
For this reason, conventional testosterone replacement therapy is generally inappropriate for men who are actively trying to conceive or plan to do so in the near future.
Fertility goals should be discussed before treatment begins.

Monitoring and Potential Risks of Therapy
Men receiving testosterone treatment require ongoing follow-up.

Monitoring may include:

• testosterone concentration;
• hematocrit;
• blood pressure;
• symptom response;
• adverse effects;
• prostate-related assessment where clinically appropriate.

An increase in hematocrit is one of the most common treatment-related concerns. A substantial rise may require dose adjustment, temporary interruption, or further clinical evaluation.

The U.S. Food and Drug Administration updated testosterone product labeling in 2025 after reviewing cardiovascular safety data. The previous boxed warning regarding myocardial infarction and stroke was removed, while information about possible increases in blood pressure was added.

Long-term safety continues to be studied, particularly in relation to cardiovascular, thromboembolic, reproductive, and prostate-related outcomes.

What the U.S. Military Program Could Mean for Other Countries
The Pentagon’s screening program may become an important case study in occupational and preventive medicine.
Similar monitoring models could be relevant to:

• military personnel in other countries;
• police and special operations units;
• firefighters;
• emergency responders;
• professional athletes;
• shift workers;
• people in physically or psychologically demanding occupations.

However, an effective program should assess more than one hormone.

A broader framework should consider:

• sleep;
• energy intake;
• body composition;
• metabolic health;
• training load;
• injuries;
• medication use;
• mental health;
• reproductive goals;
• changes over time.

The greatest value of such a program may not be the identification of more candidates for testosterone therapy.
It may be the earlier recognition of impaired recovery, metabolic dysfunction, sleep disorders, medication effects, and other treatable health problems.


Conclusion
The U.S. Department of Defense proposal to introduce annual testosterone screening for service members aged 30 and older has brought renewed attention to men’s hormonal health.
Military personnel may face several factors capable of suppressing the reproductive axis, including sleep deprivation, energy deficiency, traumatic injury, psychological stress, and extreme physical demand.
However, a testosterone result must be interpreted carefully.

The main conclusions are:

1. A single low result does not establish hypogonadism.
2. Diagnosis requires compatible symptoms and consistently low morning measurements.
3. Total testosterone should be interpreted alongside SHBG, free testosterone, LH, FSH, and the clinical context.
4. The study reporting low testosterone in 43% of elite operators was small and cross-sectional and cannot establish prevalence or causality.
5. Operator Syndrome is a proposed clinical construct, not a formally recognized diagnosis.
6. Cortisol, IGF-1, and inflammatory markers may provide additional context but are not required for every patient.
7. Obesity, sleep loss, energy deficiency, systemic illness, and medication use may cause potentially reversible hormonal suppression.
8. Evidence-based strategies include weight management, adequate nutrition, restorative sleep, regular exercise, reduced heavy alcohol use, and treatment of underlying conditions.
9. Testosterone therapy should be reserved for appropriately evaluated and confirmed deficiency.
10. Exogenous testosterone may suppress fertility and requires medical monitoring.
11. Longitudinal trends are often more informative than a single laboratory value.
12. Aima Diagnostics supports structured, personalized interpretation of hormonal and metabolic laboratory patterns.

Aima Diagnostics helps turn a laboratory report from a list of isolated values into a structured view of the patient’s biological context, biomarker relationships, and changes over time.

Key Scientific Sources

1. Endocrine Society. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
2. European Association of Urology. Guidelines on Male Hypogonadism.
3. U.S. Centers for Disease Control and Prevention. Hormone Standardization Program.
4. Edwards D. et al. Research on hormonal balance and nutritional intake in elite tactical athletes.
5. Frueh B. C. et al. Research describing the proposed Operator Syndrome construct.
6. Research on hormonal responses and recovery during military training.
7. Research on energy deficiency in military personnel.
8. U.S. Food and Drug Administration. Testosterone product labeling updates.
9. Systematic reviews examining weight loss and obesity-associated functional hypogonadism.

Medical disclaimer: This article is provided for informational purposes only. Laboratory findings and treatment decisions should be reviewed with a qualified healthcare professional. Aima Diagnostics provides laboratory interpretation support and does not replace clinical diagnosis, medical consultation, or individualized treatment.